- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | Revelation Biosciences führt Aktienzusammenlegung im Verhältnis 1 zu 7 durch | 1 | Investing.com Deutsch | ||
| 16.10. | Revelation Biosciences to implement 1-for-7 reverse stock split | 2 | Investing.com | ||
| 16.10. | Revelation Biosciences, Inc. Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 | 755 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic... ► Artikel lesen | |
| 19.08. | Revelation Biosciences vergibt gesperrte Aktienpakete an CEO und CFO | 1 | Investing.com Deutsch | ||
| 19.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Revelation Biosciences mandatiert Avance Clinical für Phase-2/3-Studie bei akuter Nierenschädigung | 1 | Investing.com Deutsch | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.08. | Revelation Biosciences selects CRO for phase 2/3 AKI study | 1 | Investing.com | ||
| 07.08. | Revelation Biosciences GAAP EPS of -$0.87 | 1 | Seeking Alpha | ||
| 06.08. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 | 529 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions... ► Artikel lesen | |
| 06.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 03.08. | Revelation Biosciences, Inc.: Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury | 442 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions... ► Artikel lesen | |
| 21.07. | Revelation Biosciences, Inc.: Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 395 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 13.07. | REVELATION BIOSCIENCES, INC. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 13.07. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights Plan | 582 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 24.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Revelation Biosciences, Inc.: Revelation Biosciences Expands Acute Kidney Injury Advisory Board | 318 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 11.05. | Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders | 711 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 08.05. | Revelation Biosciences GAAP EPS of -$2.71 | 2 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 1,270 | +3,25 % | Cellectar Biosciences meldet achtjährige Vollremission in Lymphom-Fallstudie | ||
| ONCO-INNOVATIONS | 0,145 | -2,55 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,290 | +9,32 % | CEL-SCI Corporation: CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival | Target Population Selection: Biomarker profile applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS 10%) or zero... ► Artikel lesen | |
| MOLECULIN BIOTECH | 7,579 | 0,00 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| PDS BIOTECHNOLOGY | 1,300 | +5,69 % | B.Riley hebt Kursziel für PDS Biotechnology nach Vorlage von Studiendaten an | ||
| LISATA THERAPEUTICS | 0,775 | -6,63 % | Lisata Therapeutics, Inc.: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks... ► Artikel lesen | |
| GEOVAX LABS | 0,172 | +5,52 % | EQS-News: GeoVax, Inc.: Update - GeoVax Enters Into $1 Million Revolving Loan Agreement | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
Update - GeoVax Enters Into $1 Million Revolving Loan Agreement 27.10.2026 / 13:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| COCRYSTAL | 0,915 | +5,78 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GOSSAMER BIO | 8,350 | -0,52 % | Gossamer Bio, Inc. - 8-K, Current Report | ||
| DECOY THERAPEUTICS | 1,100 | +6,80 % | Decoy Therapeutics plant Einreichung für Coronavirus-Wirkstoff im zweiten Halbjahr 2027 | ||
| JASPER THERAPEUTICS | 0,504 | -0,79 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants | REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 1,170 | -0,85 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | ||
| VISTAGEN THERAPEUTICS | 0,173 | +3,96 % | Vistagen Therapeutics streicht rund 31 % der Stellen zur Kostensenkung | ||
| IN8BIO | 0,815 | -1,81 % | IN8bio, Inc: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development | Renowned ?d T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they... ► Artikel lesen | |
| METAVIA | 1,230 | +4,24 % | MetaVia Inc. - 8-K, Current Report |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,460 (+11,36 %) liegt der Kurs bei 4,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.